Evidence map›Paper›PMID 28319200›Full record

ArticlePloS one2017

Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera.

Aziz Bitar, Rituparna De, Silvia Melgar, Kyaw Min Aung, Arman Rahman, Firdausi Qadri, Sun Nyunt Wai, Tahmina Shirin, Marie-Louise Hammarström

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Aziz BitarDepartment of Clinical Microbiology, Immunology, Umeå University, Umeå, Sweden.
Rituparna DeDepartment of Clinical Microbiology, Immunology, Umeå University, Umeå, Sweden.
Silvia MelgarAPC Microbiome Institute, University College Cork, Cork City, Ireland.
Kyaw Min AungDepartment of Clinical Microbiology, Immunology, Umeå University, Umeå, Sweden.
Arman RahmanUCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.
Firdausi QadriInternational Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh.
Sun Nyunt WaiDepartment of Molecular Biology, The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå, Sweden.
Tahmina ShirinDepartment of Virology, Institute of Epidemiology Disease Control & Research (IEDCR), National Influenza Centre (NIC), Dhaka, Bangladesh.
Marie-Louise HammarströmDepartment of Clinical Microbiology, Immunology, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0001-6182-4423
Umeå University · SEInstitute of Epidemiology, Disease Control and Research · BDInternational Centre for Diarrhoeal Disease Research · BDUniversity College Cork · IEUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential immunomodulatory role of microRNAs in small intestine of patients with acute watery diarrhea caused by Vibrio cholerae O1 or enterotoxigenic Escherichia coli (ETEC) infection was investigated. Duodenal biopsies were obtained from study-participants at the acute (day 2) and convalescent (day 21) stages of disease, and from healthy individuals. Levels of miR-146a, miR-155 and miR-375 and target gene (IRAK1, TRAF6, CARD10) and 11 cytokine mRNAs were determined by qRT-PCR. The cellular source of microRNAs in biopsies was analyzed by in situ hybridization. The ability of V. cholerae bacteria and their secreted products to cause changes in microRNA- and mRNA levels in polarized tight monolayers of intestinal epithelial cells was investigated. miR-146a and miR-155 were expressed at significantly elevated levels at acute stage of V. cholerae infection and declined to normal at convalescent stage (P<0.009 versus controls; P = 0.03 versus convalescent stage, pairwise). Both microRNAs were mainly expressed in the epithelium. Only marginal down-regulation of target genes IRAK1 and CARD10 was seen and a weak cytokine-profile was identified in the acute infected mucosa. No elevation of microRNA levels was seen in ETEC infection. Challenge of tight monolayers with the wild type V. cholerae O1 strain C6706 and clinical isolates from two study-participants, caused significant increase in miR-155 and miR-146a by the strain C6706 (P<0.01). One clinical isolate caused reduction in IRAK1 levels (P<0.05) and none of the strains induced inflammatory cytokines. In contrast, secreted factors from these strains caused markedly increased levels of IL-8, IL-1β, and CARD10 (P<0.001), without inducing microRNA expression. Thus, miR-146a and miR-155 are expressed in the duodenal epithelium at the acute stage of cholera. The inducer is probably the V. cholerae bacterium. By inducing microRNAs the bacterium can limit the innate immune response of the host, including inflammation evoked by its own secreted factors, thereby decreasing the risk of being eliminated.

Indexed as

ImmunomodulationAcute DiseaseAdultCARD Signaling Adaptor ProteinsCholeraGene Expression RegulationHumansImmunity, InnateInterleukin-1 Receptor-Associated KinasesIntestinal MucosaIntestine, SmallMaleMicroRNAsMiddle AgedTNF Receptor-Associated Factor 6Vibrio choleraeCARD10 protein, humanCARD Signaling Adaptor ProteinsInterleukin-1 Receptor-Associated KinasesIRAK1 protein, humanMicroRNAsMIRN146 microRNA, humanMIRN155 microRNA, humanTNF Receptor-Associated Factor 6

Identifiers

PMID28319200
PMCPMC5358779
OpenAlexW2597685273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.